Cover Image

The demise of metformin and the rise of the GLP‐1 agonists

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Author:	Lawrence H. Price
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	The Brown University Psychopharmacology Update
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GLP‐1 receptor agonists not associated with increased suicidality
Published: (2024)

The psychiatric benefits of cannabinoids: scarcity of evidence
by: Lawrence H. Price
Published: (2026)

Vaccines and psychiatry: Off‐target effects
by: Lawrence H. Price
Published: (2026)

Suicidality and psychotropic drugs: Another perspective
by: Lawrence H. Price
Published: (2025)

More pandemic reverberations: Focus on stimulants
by: Lawrence H. Price
Published: (2024)

Climate change and psychopharmacology
by: Lawrence H. Price
Published: (2025)

Much ado about montelukast: A side‐effects saga
by: Lawrence H. Price
Published: (2024)

Antidepressant discontinuation: Skepticism and science
by: Lawrence H. Price
Published: (2025)

The frustrating disconnect between genetics and psychopharmacology
by: Lawrence H. Price
Published: (2025)

Psychedelics and psychosis: Quantifying the risk
by: Lawrence H. Price
Published: (2025)

Concurrent metformin improves adherence to SGA treatment
Published: (2026)

Guideline includes recommendations for initiating metformin with antipsychotic
Published: (2025)

Comprehensive study of GLP‐1 effects suggests neuropsychiatric benefits
Published: (2025)

Review of GLP‐1 trials finds low incidence of suicide risk
Published: (2025)

Review finds GLP‐1s have favorable psychiatric safety profile
Published: (2025)

GLP‐1s did not increase suicide risk in patients with type 2 diabetes
Published: (2025)

Serotonin 4 receptor agonist shows promise in preventing depression
Published: (2024)

Despite adverse event risk, anti psychotic polypharmacy has continued to rise
Published: (2025)

FDA requests removal of suicide warnings from two GLP‐1 labels
Published: (2026)

Review: Research does not support most promoted medical uses of cannabis
Published: (2026)

When both treatments unblinded, psychedelics not more effective than antidepressants
Published: (2026)

Approvals
Published: (2026)

Clozapine‐induced third‐degree atrioventricular block and respiratory failure
by: Y. W. Francis Lam
Published: (2026)

Impact of maternal acetaminophen use on child neurodevelopment
by: Y. W. Francis Lam
Published: (2026)

Meta‐analysis finds little benefit from cannabinoids for behavioral disorders
Published: (2026)

Ketamine shows long‐term benefit in patients with treatment‐resistant depression
Published: (2026)

Network meta‐analysis finds dexmedetomidine broadly effective for postoperative delirium
Published: (2026)

Clozapine concentration and adverse reactions: Impact of smoking
by: Y. W. Francis Lam
Published: (2026)

Legal analysis assails FDA's lowering of standards for drug approval
Published: (2026)

Study of young psychiatric patients shows potential preventive benefit of doxycycline
Published: (2026)

Alcohol use history predicts antidepressant response to ketamine
Published: (2026)

Your Medication Information
Published: (2026)

DBT more efficacious than SSRI in reducing suicidality in borderline personality disorder
Published: (2026)

Cohort study: No causal link between psychotropic exposure and obstetric complications
Published: (2026)

Benefits of buprenorphine over methadone offset by lower treatment retention
Published: (2026)

Antipsychotic dose reduction/discontinuation in first‐episode psychosis carries short‐term risks
Published: (2026)

Decision‐support tool shows promise for treatment retention in depression
Published: (2026)

Varenicline reduces cannabis use in men in Phase 2 trial
Published: (2026)

Ketamine outperforms ECT on cognitive function in patients with treatment‐resistant depression
Published: (2026)

Paternal exposure to valproate linked to higher risk of neurodevelopmental disorders in offspring
Published: (2026)